Catalyst Funds Management’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
Other funds holding CTKB
Catalyst Funds Management's CTKB Position: Q3 2026 in Review
Catalyst Funds Management reduced its Cytek Biosciences (CTKB) stake by 22% in Q3 2026, selling an estimated $66K and leaving 48,586 shares worth $290K. The position accounts for 0.03% of the portfolio, ranked #434.
Catalyst Funds Management first reported a position in CTKB in Q1 2024 and has held it in 4 quarters since. 109 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.
- Catalyst Funds Management held 48,586 shares of Cytek Biosciences worth $290K as of Q3 2026.
- Catalyst Funds Management sold 13,914 Cytek Biosciences shares in Q3 2026, an estimated $66K.
- Cytek Biosciences made up 0.03% of Catalyst Funds Management's portfolio in Q3 2026, its #434 holding.
- Catalyst Funds Management first reported a position in Cytek Biosciences in Q1 2024 and has held it in 4 quarters since.
- 109 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.
Based on Catalyst Funds Management's 13F filing for Q3 2026, filed 12 Nov 2026.